<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822770</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0772</org_study_id>
    <nct_id>NCT00822770</nct_id>
  </id_info>
  <brief_title>Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin</brief_title>
  <official_title>G-CSF and Plerixafor With Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn about the safety of AMD3100 (plerixafor)&#xD;
      and G-CSF (filgrastim) in combination with fludarabine, busulfan, and an allogeneic blood&#xD;
      stem cell transplant. This treatment will be studied in patients with acute myeloblastic&#xD;
      leukemia (AML), myelodysplastic syndromes (MDS), or Chronic myelogenous leukemia (CML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Treatment:&#xD;
&#xD;
      Fludarabine is a chemotherapy drug that is designed to make cancer cells less able to repair&#xD;
      damaged DNA (the genetic material of cells). This may increase the likelihood of the cells&#xD;
      dying.&#xD;
&#xD;
      Busulfan is a chemotherapy drug that is designed to bind to DNA, which may cause cancer cells&#xD;
      to die. It is commonly used in stem cell transplants.&#xD;
&#xD;
      Plerixafor and filgrastim are designed to cause cancer cells to move from the bone marrow&#xD;
      into the blood stream. This may help to make the cancer cells more sensitive to being killed&#xD;
      by the chemotherapy.&#xD;
&#xD;
      An &quot;allogeneic&quot; (from a donor) stem cell transplant is designed to help the recipient's body&#xD;
      attack the cancer cells that may remain in the body after chemotherapy.&#xD;
&#xD;
      Study Groups and Plerixafor Dose Levels:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      group based on when you joined this study. Up to 4 groups of 3 participants will be enrolled&#xD;
      in the Phase I portion of the study, and up to 48 participants will be enrolled in Phase II.&#xD;
&#xD;
      If you are enrolled in the Phase I portion, the dose of plerixafor you receive will depend on&#xD;
      when you joined this study. The first group of participants will receive the lowest dose&#xD;
      level of plerixafor. Each new group will receive a higher dose of plerixafor than the group&#xD;
      before it, if no intolerable side effects were seen. This will continue until the highest&#xD;
      tolerable dose of plerixafor is found.&#xD;
&#xD;
      If you are enrolled in Phase II, you will receive plerixafor at the highest dose that was&#xD;
      tolerated in the Phase I portion.&#xD;
&#xD;
      In this study, plerixafor is the only study drug where different dose levels are being tested&#xD;
      and compared.&#xD;
&#xD;
      Drug Administration Before the Transplant:&#xD;
&#xD;
      You will receive your first dose of filgrastim on Day -9. (Day -9 means 9 days before the&#xD;
      stem cell transplant, which will occur on Day 0).&#xD;
&#xD;
      Filgrastim is injected under the skin once a day from Day -9 through Day -4. Plerixafor is&#xD;
      injected under the skin once a day from Day -7 through Day -4. The plerixafor injections will&#xD;
      occur 8 hours before the fludarabine and busulfan chemotherapy.&#xD;
&#xD;
      The fludarabine and busulfan will be given by vein through a central venous catheter (CVC). A&#xD;
      CVC is a sterile flexible tube that will be placed into a large vein while you are under&#xD;
      local anesthesia. Your doctor will explain this procedure to you in more detail, and you will&#xD;
      be required to sign a separate consent form for this procedure.&#xD;
&#xD;
      Fludarabine is given once a day from Day -6 through Day -3, over 1 hour each time. On these&#xD;
      same days, busulfan will be given after the fludarabine, over 3 hours.&#xD;
&#xD;
      You will also receive tacrolimus in order to lower the risk of graft vs. host disease (GVHD).&#xD;
      GVHD is a disease that occurs when the donor's immune cells react against the recipient's&#xD;
      body, attacking the recipient's cells and tissues.&#xD;
&#xD;
      Starting on Day -2, tacrolimus will be given as a continuous (non-stop) infusion through the&#xD;
      CVC. When the study doctor decides it seems safe, you will begin taking tacrolimus by mouth&#xD;
      instead, for as long as the study doctor decides is necessary.&#xD;
&#xD;
      If your stem cell donor is not someone who is related to you, you will receive antithymocyte&#xD;
      globulin (ATG) through the CVC once a day from Day -3 through Day -1. On Day -3, it will be&#xD;
      given over at least 6 hours. On Days -2 and -1, it will be given over at least 4 hours. This&#xD;
      drug is given in order to weaken your immune system in order to lower the risk of your immune&#xD;
      system rejecting the transplanted cells.&#xD;
&#xD;
      Blood Tests Before the Transplant:&#xD;
&#xD;
      If you are in the Phase I part of this study, the following blood samples will be drawn and&#xD;
      are not optional. Eight total blood samples (about 1 1/2 teaspoons each) will be drawn daily&#xD;
      with your routine morning labs beginning before your first dose of study therapy (or Day -9)&#xD;
      through Day -3. These samples will be used for research purposes, to study how the&#xD;
      chemotherapy drugs and transplant may affect your normal cells and cancerous cells.&#xD;
&#xD;
      If you are in the Phase II part of the study the following blood samples are optional and if&#xD;
      you agree, eight total blood samples (about 1 1/2 teaspoons each) will be drawn daily&#xD;
      beginning before your first dose of study therapy (or Day -9) through Day -3. These samples&#xD;
      will be used for research purposes, to study how the chemotherapy drugs and transplant may&#xD;
      affect your normal cells and cancerous cells.&#xD;
&#xD;
      Stem Cell Transplant:&#xD;
&#xD;
      On Day 0, after 2 days of rest from chemotherapy, the donor's stem cells will be given to you&#xD;
      by vein (through the CVC). This should take about 30-60 minutes.&#xD;
&#xD;
      Drug Administration After the Transplant:&#xD;
&#xD;
      In addition to continuing to receive tacrolimus to lower the risk of GVHD (as described&#xD;
      above), after the transplant you will also receive methotrexate to lower the risk of GVHD.&#xD;
      Methotrexate will be given by vein, through the CVC, over 15 minutes on Days 1, 3, and 6. It&#xD;
      will also be given on Day 11 if your stem cell donor is someone who is not related to you.&#xD;
&#xD;
      Once a day, starting at 1 week after the transplant, you will receive filgrastim as an&#xD;
      injection under your skin. These daily injections will continue until your blood counts&#xD;
      recover.&#xD;
&#xD;
      Reasons for Stopping the Study Treatment Early:&#xD;
&#xD;
      If you experience intolerable side effects or the disease gets worse during study treatment,&#xD;
      you will be taken off the study treatment.&#xD;
&#xD;
      Other Procedures After the Transplant:&#xD;
&#xD;
      You will remain in the hospital until your blood counts recover (usually about 4 weeks after&#xD;
      the transplant). You will continue being monitored for any infections and transplant-related&#xD;
      side effects for at least 100 days after the transplant.&#xD;
&#xD;
      At 1, 3, 6, and 12 months after the transplant, you will have blood tests (about 3&#xD;
      tablespoons) and bone marrow biopsies performed to check the status of the disease.&#xD;
&#xD;
      Length of Study Participation:&#xD;
&#xD;
      Your active participation in this study will be over at 12 months after the transplant. The&#xD;
      study staff will continue to contact your local doctor regularly from then on. The purpose is&#xD;
      to check the status of the disease and see how you are doing.&#xD;
&#xD;
      Up to 72 patients will take part in this study. All will be enrolled at The University of&#xD;
      Texas (UT) MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade 4 Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) Plerixafor</measure>
    <time_frame>28 day cycle (Plerixafor Day -7 to Day -4)</time_frame>
    <description>Phase I determination of MTD dose of Plerixafor in combination with a fixed dose of Filgrastim where dose limiting toxicity defined as any grade 4 non-hematologic toxicity observed within 28 days from Day 0 (day of transplant).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Alive With no Disease Progression at Time of Allo Transplant</measure>
    <time_frame>Baseline till transplant, Day -9 to Day 0, to 10 days</time_frame>
    <description>In Phase II portion of study, number of participants with treatment failure defined as either disease recurrence or death, measured from start of treatment to allo transplant at Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment Response Rate: Number of Transplanted Participants With Complete Chimerism at Day 30</measure>
    <time_frame>30 Days post engraftment</time_frame>
    <description>Number of participants with complete chimerism at day 30 where defined as: Engraftment: first day of three (3) consecutive days that Absolute neutrophil count (ANC) exceeds 0.5 X 109/L. Subsequent chimerism studies must demonstrate the presence of donor derived cells. Graft Failure: failure to achieve an ANC &gt;0.5 X 109/L for 3 consecutive days within 28 days after transplantation or a decline of ANC &lt;0.5 x 109/L for three consecutive days after initial documented engraftment unless this is correlated with progression / recurrence of the underlying malignancy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Stem Cell Transplantation</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG + MTD Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.&#xD;
Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>AMD3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Busulfex™</other_name>
    <other_name>Myleran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic blood stem cell transplant</intervention_name>
    <description>Stem Cell Infusion (Bone marrow or PBPC)</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Bone Marrow Transplantation</other_name>
    <other_name>Blood Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG (Thymoglobulin)</intervention_name>
    <description>Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Antithymocyte globulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients age &gt;/=18 to &lt;/= 65 years.&#xD;
&#xD;
          2. Diagnosis of AML in first or greater remission, first or subsequent relapse, or&#xD;
             primary induction failure; MDS with intermediate or high risk International Prognostic&#xD;
             Scoring System (IPSS) score having failed to respond or recurred after chemotherapy;&#xD;
             in remission or having active disease after treatment; AML arising from MDS; or CML&#xD;
             which has failed to respond to imatinib or other tyrosine kinase inhibitor and has had&#xD;
             &gt;5% blasts in the blood or bone marrow. Patients receiving second transplants after&#xD;
             relapse are considered in the relapse group.&#xD;
&#xD;
          3. White Blood Count (CBC) &lt;/= 20 * 10^9/l.&#xD;
&#xD;
          4. Patients should have a histocompatible, related or unrelated volunteer donor&#xD;
             available. A histocompatible donor is defined as HLA matched related donor or an&#xD;
             unrelated donor matched for HLA- A, B, C, and DR antigens by high-resolution DNA&#xD;
             techniques.&#xD;
&#xD;
          5. Zubrod performance status 0 or 1, or Karnofsky performance status 90-100%.&#xD;
&#xD;
          6. Left ventricular ejection fraction &gt;/= 45 %. No uncontrolled arrhythmias or&#xD;
             uncontrolled symptomatic cardiac disease.&#xD;
&#xD;
          7. No symptomatic pulmonary disease. Forced expiratory volume in 1 s (FEV1), forced vital&#xD;
             capacity (FVC) and diffusion capacity of carbon monoxide (DLCO) &gt;/= 50 % of expected,&#xD;
             corrected for hemoglobin.&#xD;
&#xD;
          8. Serum creatinine &lt;/=1.5 mg/dl.&#xD;
&#xD;
          9. Serum glutamic pyruvic transaminase (SGPT) &lt;/= 200 IU/ml unless related to the&#xD;
             malignancy.&#xD;
&#xD;
         10. Total serum bilirubin &lt;/=1.5 mg/dl (unless Gilbert's syndrome) and alkaline&#xD;
             phosphatase &lt;/=2.5 times laboratory standard upper limit of normal (ULN).&#xD;
&#xD;
         11. Patient or patient's legal representative able to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of HIV positive.&#xD;
&#xD;
          2. Positive Beta human chorionic gonadotropin (HCG) test in a woman with child bearing&#xD;
             potential defined as not post-menopausal for 12 months or no previous surgical&#xD;
             sterilization.&#xD;
&#xD;
          3. Pleural/pericardial effusion or ascites estimated &gt;/= 1 liter.&#xD;
&#xD;
          4. Uncontrolled infection, not responding to appropriate antimicrobial agents after seven&#xD;
             days of therapy.&#xD;
&#xD;
          5. History of acute hepatitis, chronic active hepatitis or cirrhosis.&#xD;
&#xD;
          6. Patients with class 3 or 4 angina (New York Heart Association (NYHA) criteria).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Konopleva, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <results_first_submitted>June 13, 2014</results_first_submitted>
  <results_first_submitted_qc>June 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Stem Cell Transplantation</keyword>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>Bone Marrow Cell Transplantation</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Allogeneic Hematopoietic Transplantation</keyword>
  <keyword>Advanced Myeloid Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Graft Versus Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>ATG</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Busulfex™</keyword>
  <keyword>Myleran®</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Fludara™</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Plerixafor</keyword>
  <keyword>Antithymocyte globulin</keyword>
  <keyword>Thymoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Plerixafor</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: January 2, 2009 to February 1, 2012. All recruitment done at the University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I Plerixafor + G-CSF</title>
          <description>Plerixafor (AMD3100) Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses + Thymoglobulin (ATG) 0.5 mg/kg on day -3; 1.5 mg/kg on day -2; &amp; 2 mg/kg on day -1. Given only to patients with unrelated donors + G-CSF (Filgrastim) 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days + Fludarabine 40 mg/m^2 beginning on Day -6 for four consecutive days + Busulfan 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine + Allogeneic blood stem cell transplant of Stem Cell Infusion (Bone marrow or PBPC)</description>
        </group>
        <group group_id="P2">
          <title>Phase II Plerixafor 240 mcg/kg + G-CSF</title>
          <description>Plerixafor Phase I Maximum Tolerated Dose (MTD) 240 mcg/kg daily for 4 days starting Day -7 + ATG 0.5 mg/kg day -3; 1.5 mg/kg on day -2; &amp; 2 mg/kg on day -1 only for participants with unrelated donors + G-CSF 10 mcg/kg subcutaneous injection beginning day -9 daily for 6 days + Fludarabine 40 mg/m^2 beginning on Day -6 for four consecutive days + Busulfan 130 mg/m^2 for 4 consecutive days, immediately after completion of Fludarabine + Allogeneic blood stem cell transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Complication/Incomplete treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I Plerixafor + G-CSF</title>
          <description>Plerixafor (AMD3100) Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses + Thymoglobulin (ATG) 0.5 mg/kg on day -3; 1.5 mg/kg on day -2; &amp; 2 mg/kg on day -1. Given only to patients with unrelated donors + G-CSF (Filgrastim) 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days + Fludarabine 40 mg/m^2 beginning on Day -6 for four consecutive days + Busulfan 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine + Allogeneic blood stem cell transplant of Stem Cell Infusion (Bone marrow or PBPC)</description>
        </group>
        <group group_id="B2">
          <title>Phase II Plerixafor 240 mcg/kg + G-CSF</title>
          <description>Plerixafor Phase I Maximum Tolerated Dose (MTD) 240 mcg/kg daily for 4 days starting Day -7 + ATG 0.5 mg/kg day -3; 1.5 mg/kg on day -2; &amp; 2 mg/kg on day -1 only for participants with unrelated donors + G-CSF 10 mcg/kg subcutaneous injection beginning day -9 daily for 6 days + Fludarabine 40 mg/m^2 beginning on Day -6 for four consecutive days + Busulfan 130 mg/m^2 for 4 consecutive days, immediately after completion of Fludarabine + Allogeneic blood stem cell transplant.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="41" upper_limit="65"/>
                    <measurement group_id="B2" value="53" lower_limit="25" upper_limit="65"/>
                    <measurement group_id="B3" value="55" lower_limit="25" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 4 Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) Plerixafor</title>
        <description>Phase I determination of MTD dose of Plerixafor in combination with a fixed dose of Filgrastim where dose limiting toxicity defined as any grade 4 non-hematologic toxicity observed within 28 days from Day 0 (day of transplant).</description>
        <time_frame>28 day cycle (Plerixafor Day -7 to Day -4)</time_frame>
        <population>Two participants of 18 registered left the study without receiving Plerixafor treatment and there were not available for MTD analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Plerixafor + G-CSF</title>
            <description>ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant&#xD;
Allogeneic blood stem cell transplant : Stem Cell Infusion (Bone marrow or PBPC)&#xD;
Filgrastim : Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.&#xD;
Fludarabine : Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.&#xD;
ATG (Thymoglobulin) : Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.&#xD;
Busulfan : Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.&#xD;
Plerixafor : Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 4 Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) Plerixafor</title>
          <description>Phase I determination of MTD dose of Plerixafor in combination with a fixed dose of Filgrastim where dose limiting toxicity defined as any grade 4 non-hematologic toxicity observed within 28 days from Day 0 (day of transplant).</description>
          <population>Two participants of 18 registered left the study without receiving Plerixafor treatment and there were not available for MTD analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 mcg/kg daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 mcg/kg daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>160 mcg/kg daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 mcg/kg daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Alive With no Disease Progression at Time of Allo Transplant</title>
        <description>In Phase II portion of study, number of participants with treatment failure defined as either disease recurrence or death, measured from start of treatment to allo transplant at Day 0.</description>
        <time_frame>Baseline till transplant, Day -9 to Day 0, to 10 days</time_frame>
        <population>Participants treated in the Phase 1 portion of the trial at the selected MTD dose were counted toward the maximum subgroup sample in Phase 2, therefore four of Phase I participants were included having received the MTD Plerixafor dose; however, one late participant in Phase 2 was not evaluable for the outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study: Plerixafor + G-CSF</title>
            <description>Plerixafor escalating doses 0, 80, 160, 240 mcg/kg or MTD 240 mcg/kg given daily subcutaneously in abdomen for 4 doses + Thymoglobulin (ATG) 0.5 mg/kg on day -3; 1.5 mg/kg on day -2; &amp; 2 mg/kg on day -1. Given only to patients with unrelated donors + G-CSF (Filgrastim) 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days + Fludarabine 40 mg/m^2 beginning on Day -6 for four consecutive days + Busulfan 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine + Allogeneic blood stem cell transplant of Stem Cell Infusion (Bone marrow or PBPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Alive With no Disease Progression at Time of Allo Transplant</title>
          <description>In Phase II portion of study, number of participants with treatment failure defined as either disease recurrence or death, measured from start of treatment to allo transplant at Day 0.</description>
          <population>Participants treated in the Phase 1 portion of the trial at the selected MTD dose were counted toward the maximum subgroup sample in Phase 2, therefore four of Phase I participants were included having received the MTD Plerixafor dose; however, one late participant in Phase 2 was not evaluable for the outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants not in Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Engraftment Response Rate: Number of Transplanted Participants With Complete Chimerism at Day 30</title>
        <description>Number of participants with complete chimerism at day 30 where defined as: Engraftment: first day of three (3) consecutive days that Absolute neutrophil count (ANC) exceeds 0.5 X 109/L. Subsequent chimerism studies must demonstrate the presence of donor derived cells. Graft Failure: failure to achieve an ANC &gt;0.5 X 109/L for 3 consecutive days within 28 days after transplantation or a decline of ANC &lt;0.5 x 109/L for three consecutive days after initial documented engraftment unless this is correlated with progression / recurrence of the underlying malignancy.</description>
        <time_frame>30 Days post engraftment</time_frame>
        <population>There were 39 participants receiving first transplants for acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) of both Phase I and Phase II who received MTD dose and allo transplant thus were evaluable for outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study: Plerixafor + G-CSF</title>
            <description>Plerixafor escalating doses 0, 80, 160, 240 mcg/kg or MTD 240 mcg/kg given daily subcutaneously in abdomen for 4 doses + Thymoglobulin (ATG) 0.5 mg/kg on day -3; 1.5 mg/kg on day -2; &amp; 2 mg/kg on day -1. Given only to patients with unrelated donors + G-CSF (Filgrastim) 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days + Fludarabine 40 mg/m^2 beginning on Day -6 for four consecutive days + Busulfan 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine + Allogeneic blood stem cell transplant of Stem Cell Infusion (Bone marrow or PBPC)</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment Response Rate: Number of Transplanted Participants With Complete Chimerism at Day 30</title>
          <description>Number of participants with complete chimerism at day 30 where defined as: Engraftment: first day of three (3) consecutive days that Absolute neutrophil count (ANC) exceeds 0.5 X 109/L. Subsequent chimerism studies must demonstrate the presence of donor derived cells. Graft Failure: failure to achieve an ANC &gt;0.5 X 109/L for 3 consecutive days within 28 days after transplantation or a decline of ANC &lt;0.5 x 109/L for three consecutive days after initial documented engraftment unless this is correlated with progression / recurrence of the underlying malignancy.</description>
          <population>There were 39 participants receiving first transplants for acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) of both Phase I and Phase II who received MTD dose and allo transplant thus were evaluable for outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The active treatment period defined as study entry through Stem Cell Transfusion Day +28, follow up defined as Transfusion Day +29 through Day +100.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I Plerixafor + G-CSF</title>
          <description>ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant:&#xD;
Plerixafor (AMD3100) Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses + Thymoglobulin (ATG) 0.5 mg/kg on day -3; 1.5 mg/kg on day -2; &amp; 2 mg/kg on day -1. Given only to patients with unrelated donors + G-CSF (Filgrastim) 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days + Fludarabine 40 mg/m^2 beginning on Day -6 for four consecutive days + Busulfan 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine + Allogeneic blood stem cell transplant of Stem Cell Infusion (Bone marrow or PBPC)</description>
        </group>
        <group group_id="E2">
          <title>Phase II Plerixafor 240 mcg/kg + G-CSF</title>
          <description>Plerixafor Phase I Maximum Tolerated Dose (MTD) 240 mcg/kg daily for 4 days starting Day -7 + ATG 0.5 mg/kg day -3; 1.5 mg/kg on day -2; &amp; 2 mg/kg on day -1 only for participants with unrelated donors + G-CSF 10 mcg/kg subcutaneous injection beginning day -9 daily for 6 days + Fludarabine 40 mg/m^2 beginning on Day -6 for four consecutive days + Busulfan 130 mg/m^2 for 4 consecutive days, immediately after completion of Fludarabine + Allogeneic blood stem cell transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System (CNS) hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic cyctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>with Cytomegalovirus (CMV)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus Host Disease, Skin Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated White Blood Count</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High Blood Pressure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Change in cardiac function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="25" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like Symptoms</sub_title>
                <description>Fever, chills</description>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="18"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="36" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Graft versus Host Disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase Increase</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders: Changes within blood level</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Genitourinary disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Infection, Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marina Konopleva, MD, PhD / Associate Professor</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-794-1628</phone>
      <email>mkonople@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

